Immunotherapy has revolutionized the treatment of hematologic malignancies in the last decade, with multiple agents being approved by the FDA in recent years. While various approaches are used to modify the anti-tumor immunity of the host, perhaps the most commonly studied and used is checkpoint blockade. Treatment of relapsed/refractory non-Hodgkin lymphoma remains challenging.

Data are being generated with checkpoint inhibitors given in monotherapy and in combination with other treatment modalities, including conventional chemotherapy, small-molecule inhibitors, and other immune therapies. Therefore, the importance must be in the unique immune-related adverse events, which warrant close monitoring in some cases, and on the identification of biomarkers that predict response or severe adverse events.

This Special Issue aims to collate original research articles with a focus on checkpoint inhibitors in non-Hodgkin lymphomas, as well as review articles that discuss the current state of the art.

Potential topics include but are not limited to the following:

• Preclinical results with checkpoint inhibitors as single agents and in combination in non-Hodgkin lymphoma models
• Clinical results with checkpoint inhibitors as single agents and in combination for non-Hodgkin lymphoma patients
• Patterns of side effects of checkpoint inhibitors and their management in non-Hodgkin lymphoma patients
• Biomarkers of response to checkpoint inhibitors in non-Hodgkin lymphoma patients
• How non-Hodgkin lymphoma tumor microenvironment can affect the response to checkpoint inhibitors